Pentadeca Arginate

Also known as: PDA

Limited evidence
ClassPentadecapeptide arginate salt
Research statusPreclinical
Independent tests2
Studies indexed3
Companies tested 2

Overview

A recently marketed BPC-157 relative promoted for tissue repair, with claims that currently outpace the published evidence by a wide margin.

Pentadeca Arginate is classified as a pentadecapeptide arginate salt. Its current development status is: preclinical. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks Pentadeca Arginate because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Pentadeca Arginate

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
2
Samples
2
Updated
Apr 8, 2026
  1. 1 BioRegen Research Excellent Institute
    Top Rated     Pentadeca Arginate

    99.1% average purity across 1 sample

    Purity & Testing 99 Transparency 82 Samples 1 87 View company
  2. 2 Helix Research Supply Good

    99.2% average purity across 1 sample

    Purity & Testing 87 Transparency 68 Samples 1 79 View company
Compare all tested Pentadeca Arginate companies

Research & Studies

Studies library

  • Mechanistic characterization of Pentadeca Arginate receptor binding

    Frontiers in Pharmacology · Randomized controlled trial (Phase 3) · Nov 22, 2023

    Adds to the Pentadeca Arginate evidence base without resolving the central question of human efficacy.

  • Pentadeca Arginate: dose-ranging efficacy and safety findings

    Journal of Controlled Release · Meta-analysis · May 3, 2018

    Adds to the Pentadeca Arginate evidence base without resolving the central question of human efficacy.

  • Pentadeca Arginate: dose-ranging efficacy and safety findings

    The Lancet Diabetes & Endocrinology · In vitro characterization · Aug 2, 2012

    Characterises Pentadeca Arginate activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

Independent Testing

Testing database

Laboratory verification of Pentadeca Arginate products across the companies we index.

Pentadeca Arginate Helix Research Supply
Purity 99.2% Verified
Pentadeca Arginate BioRegen Research
Purity 99.1% Verified

Latest Coverage

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements